News | November 03, 2010

CE Mark Study Begins for Transapical TAVI System

November 3, 2010 – A multicenter CE-mark study has been launched for transapical TAVI system. Hendrik Treede, M.D., performed the first implantations of the system, made by JenaValve, at the Universitäres Herzzentrum Hamburg.

The JenaValve transapical TAVI system is designed for the treatment of severe stenotic aortic valve disease in elderly high-risk patients, especially those unsuitable for conventional open heart surgery.

Its design enables physicians to advance, rotate, reposition or retract the feelers as necessary, leading to correct and precise placement of the prosthesis.

“The study is important because, if approved, it may identify a new transapical TAVI system generation which promises precise implantation and ease-of-handling for physicians," said Friedrich-Wilhelm Mohr, M.D., Ph.D., director of the clinic for cardiac surgery, Heart Center Leipzig and principal investigator of the study.

The company anticipates completion of patient enrollment in the first quarter of 2011 and CE-mark approval in the third quarter of 2011.

For more information:

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Overlay Init